Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.

JCI insight·2025
Same author

Characteristics of youth utilizing pediatric dermatology: A cross-sectional PEDSnet study.

Journal of the American Academy of Dermatology·2025
Same author

Development and Validation of a Scale to Assess Epidermolysis Bullosa Simplex Severity.

JAMA dermatology·2025
Same author

Dupilumab Reduces Pruritus in Twins With Sjögren-Larsson Syndrome.

Pediatric dermatology·2025
Same author

Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.

Dermatology and therapy·2025
Same author

Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry.

American journal of clinical dermatology·2025

相关实验视频

Updated: Jun 29, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.6K

在Dupilumab第3期无氧皮肤炎试验中的面部皮疹事件:综合分析

Amy S Paller1,2, Marjolein de Bruin-Weller3, Eric L Simpson4

  • 1From the Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Dermatitis : contact, atopic, occupational, drug
|October 30, 2025
PubMed
概括
此摘要是机器生成的。

与安慰剂相比,治疗中度至重度的亚托皮炎 (AD) 的杜皮卢马布显示,面部皮疹治疗出现的不良事件 (TEAE) 略有增加. 大多数面部皮疹病例是轻度至中度的,并且在不停止治疗的情况下得到解决.

关键词:
亚托邦性皮肤炎的发生双重复制的马布.面部皮疹 面部皮疹

更多相关视频

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.5K
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

606

相关实验视频

Last Updated: Jun 29, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.6K
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.5K
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

606

科学领域:

  • 皮肤病学 皮肤病学
  • 临床药理学 临床药理学

背景情况:

  • 2017年批准用于中度至重度亚托邦性皮炎 (AD) 的杜皮卢马布 (Dupilumab) 在营销后文献中与面部皮疹的报告有关.
  • 了解面部皮疹的发生率和特征对于患者管理至关重要.

研究的目的:

  • 在参与dupilumab临床试验的中度至重度AD患者中量化面部皮疹治疗出现的不良事件 (TEAE) 的发生率.
  • 使用MedDRA最低水平术语 (LLT) 分析特定的面部皮疹事件.

主要方法:

  • 从14个随机,安慰剂控制的临床试验中汇集了数据,这些临床试验涉及中度至重度AD的儿科和成人患者.
  • 在研究治疗期间,系统地搜索面部皮疹TEAE,按MedDRA LLTs分类.

主要成果:

  • 这项研究包括1349名安慰剂治疗和2615名杜皮卢马布治疗的患者.
  • 面部皮疹发病率较低,但与安慰剂 (0.7%) 相比,dupilumab组 (1.0%) 的数量较高.
  • 特定的LLT,如面部红血,面部发红和面部皮疹,在dupilumab. 大多数事件都是轻度至中度,并得到解决.

结论:

  • 在对中度至重度阿尔茨海默病的杜皮卢马布试验中对MedDRA LLTs的分析表明,与安慰剂相比,面部皮疹发病率略有增加.
  • 观察到的面部皮疹主要是轻度至中度的,不需要停止治疗,这表明这种不良事件的安全性是可以管理的.